Treatment of Infants and Children With SARS-CoV-2 Monoclonal Antibodies: A European Case Series.
Pediatr Infect Dis J
; 42(2): 125-129, 2023 02 01.
Article
in English
| MEDLINE | ID: covidwho-2190925
ABSTRACT
BACKGROUND:
Although severe COVID-19 in children is rare, those with certain pre-existing health conditions are more prone to severe disease. Monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are potent antiviral agents that reduce adverse clinical outcomes in adults, but are commonly not approved for use in pediatric patients.METHODS:
We retrospectively evaluated mAb treatment in children <12 years of age or <40kg with SARS-CoV-2 infection between January 1, 2021, and March 7, 2022, in 12 tertiary care centers in 3 European countries.RESULTS:
We received data from 53 patients from Austria, Denmark and Germany. Median age was 5.4 years [0-13.8, interquartile range (IQR) = 6.2], and median body weight was 20 kg (3-50.1, IQR = 13). The most frequent SARS-CoV-2 variant in this study, if known, was Omicron, followed by Delta and Alpha. Pre-existing conditions included immunodeficiency, malignancy, hematologic disease, cardiac disease, chronic lung disease, chronic liver disease, kidney disease and diabetes. Forty-two patients received sotrovimab (79%), 9 casirivimab/imdevimab (17%) and 2 bamlanivimab (4%). All but 1 patient survived. Median duration of hospital stay was 3 days (0-56, IQR = 6). Seven patients required treatment in an intensive care unit, and 5 required high-flow nasal cannula treatment. Potential side effects included neutropenia (6/53, 11%), lymphopenia (3/53, 6%), nausea or vomiting (2/53, 4%), rise of alanine transaminase (1/53, 2%) and hypotonia (1/53, 2%).CONCLUSIONS:
MAb treatment was well tolerated by children in this cohort.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Leukopenia
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
Topics:
Variants
Limits:
Adult
/
Child
/
Child, preschool
/
Humans
/
Infant
Language:
English
Journal:
Pediatr Infect Dis J
Journal subject:
Communicable Diseases
/
Pediatrics
Year:
2023
Document Type:
Article
Affiliation country:
Inf.0000000000003773
Similar
MEDLINE
...
LILACS
LIS